Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study

Table 3 Numbers and percentages (with 95% CI) of cleared oral high-risk HPV infections in HIV-negative and HIV-infected MSM ^a (H2M study, Amsterdam 2010–2012)

	12-month clearance of oral high-risk HPV infections
	HIV-negative MSM			HIV-infected MSM
	No.	%	95% CI	No.	%	95% CI	P -value ^b
HPV-16	5/9	55.6	(21.2 - 86.3)	5/13	38.5	(13.9 - 68.4)	0.666
HPV-18	2/3	66.7	(9.4 - 99.2)	3/6	50.0	(11.8 - 88.2)	1.000
HPV-31	1/1	100.0	(2.5 - 100.0)^c	5/7	71.4	(29.0 - 96.3)	1.000
HPV-33	1/3	33.3	(0.8 - 90.6)	1/12	8.3	(0.2 - 38.5)	0.371
HPV-35	1/5	20.0	(0.5 - 71.6)	1/3	33.3	(0.8 - 90.6)	1.000
HPV-39	4/4	100.0	(39.8 - 100.0)^c	2/6	33.3	(4.3 - 77.7)	0.076
HPV-45	0/0	-	-	5/5	100.0	(47.8 -100.0)^c	-
HPV-51	5/6	83.3	(35.9 - 99.6)	3/5	60.0	(14.7 - 94.7)	0.545
HPV-52	3/3	100.0	(29.2 - 100.0)^c	3/4	75.0	(19.4 - 99.4)	1.000
HPV-56	1/2	50.0	(1.3 - 98.7)	5/9	55.6	(21.2 - 86.3)	1.000
HPV-58	0/0	-	-	1/2	50.0	(1.3 - 98.7)	-
HPV-59	2/2	100.0	(15.8 - 100.0)^c	0/1	0.0	(0.0 -97.5)^c	0.333

Abbreviations: MSM men who have sex with men, No. number, CI confidence interval.
^aClearance was defined as two consecutive negative results after a positive test result at baseline (1-0-0), persistence was defined as two consecutive positive results after a positive test result at baseline (1-1-1), other infection patterns (1-0-1 or 1-1-0) did not meet criteria for either clearance or persistence.
^bBased on Fisher’s exact test.
^cOne-sided: 97.5% CI.

ISSN: 1471-2334